Developing a neuroprotective therapy for Parkinson’s and Huntington’s diseases

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.17, Iss.2, 2007-02, pp. : 159-172

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Histone Post-translational Modifications in Huntington’s and Parkinson’s Diseases

Current Pharmaceutical Design, Vol. 19, Iss. 28, 2013-04 ,pp. : 5085-5092

Bentham Science Publishers

Access to resources Recommend Favorite

GABA signalling: therapeutic targets for epilepsy, Parkinson’s disease and Huntington’s disease

By Kleppner S.R. Tobin A.J.

Expert Opinion on Therapeutic Targets, Vol. 5, Iss. 2, 2001-04 ,pp. : 219-239

Informa Healthcare

Access to resources Recommend Favorite

Transplantation therapy for Parkinson’s disease

By Borlongan C.V.

Expert Opinion on Investigational Drugs, Vol. 9, Iss. 10, 2000-10 ,pp. : 2319-2330

Informa Healthcare

Access to resources Recommend Favorite

Neuroprotection in Huntington;s Disease

Letters in Drug Design & Discovery, Vol. 2, Iss. 2, 2005-03 ,pp. : 143-147

Bentham Science Publishers

Access to resources Recommend Favorite

Gene therapy for Parkinson’s disease: review and update

By Kang U.J. Frim D.M.

Expert Opinion on Investigational Drugs, Vol. 8, Iss. 10, 1999-10 ,pp. : 1551-1564

Informa Healthcare

Access to resources Recommend Favorite